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Paclitaxel is an alkaloid that inhibits endothelial cell
proliferation, motility, and tube formation at nanomo-
lar concentrations. Cationic liposome preparations have
been shown to target blood vessels. We wished to ex-
plore the possibility that paclitaxel encapsulated in ca-
tionic liposomes carries paclitaxel to blood vessels and
thereby provides an antiangiogenic e¡ect.We used a hu-
manized SCID mouse melanoma model, which al-
lowed us to analyze tumor growth and tumor
angiogenesis in an orthotopic tumor model. Here, hu-
man melanoma cells grow on human dermis and are
in part nourished by human vessels.We show that pacli-
taxel encapsulated in liposomes prevents melanoma
growth and invasiveness and improves survival of mice.
Moreover, liposome-encapsulated paclitaxel reduces
vessel density at the interface between the tumor and
the human dermis and reduces endothelial cell mitosis
to background levels. In contrast, equimolar concentra-
tions of paclitaxel solubilized in Cremophor ELs had
only insigni¢cant e¡ects on tumor growth and did not
reduce the mitotic index of endothelium in vivo,
although the antiproliferative e¡ect of solubilized pacli-
taxel in Cremophor ELs in vitro was identical to that
seen with liposome-coupled paclitaxel. In conclusion,
we present a model of how to exploit cytotoxic e¡ects
of compounds to prevent tumor growth by using catio-
nic liposomes for targeting an antiproliferative drug
to blood vessels. Key words: antiangiogenesis/catio-
nic liposomes/melanoma/paclitaxel/SCID mouse. J Invest
Dermatol 120:476 ^482, 2003
T
he hypothesis that tumor growth and metastasis de-
pend on angiogenesis was ¢rst proposed in 1971
(Folkman, 1971). In its simplest terms, it says: Once
tumor ‘‘take’’ has occurred, every increase in tumor
cell population must be preceded by an increase in
new capillaries converging onto the tumor. Tumor ‘‘take’’ is cur-
rently understood as a prevascular phase of tumor growth in
which a population of tumor cells occupying a few cubic milli-
meters of volume is nourished by and can survive on the existing
host microvessels (dormant tumor). Tumor growth beyond this
size requires new vessel formation (angiogenesis) and inhibition
of angiogenesis prevents tumor growth. The principles of antian-
giogenic treatment to prevent tumor growth have been proved in
many di¡erent tumor models and are the basis of many clinical
trials (Carmeliet and Jain, 2000). Strategies include the interfer-
ence with angiogenic ligands [e.g., with vascular endothelial
growth factor and its receptors (Carmeliet and Jain, 2000)]
or the induction of angiogenic inhibitors [e.g., angiostatin and
endostatin (O’Reilly et al, 1998)]. As tumors and the tumor stro-
ma may produce an array of angiogenic molecules or even switch
to another molecule if one pathway is blocked, it has to be ex-
pected that a cocktail of antiangiogenic reagents will be needed
to e¡ectively prevent angiogenesis (Carmeliet and Jain, 2000).
An alternative approach is to directly target the tumor vasculature
and, for example, induce thrombosis of tumor vessels (Hu and
Garen, 2001; Nilsson et al, 2001), but the existence of a tumor-ves-
sel-speci¢c ‘‘zip code’’ has to be validated. Considering that in the
normal adult the majority of vascular endothelial cells are quies-
cent, with only 0.01% of cells undergoing division (Carmeliet
and Jain, 2000), whereas in the tumor vasculature up to 25% of
endothelial cells divide (Brien et al, 1989), the problem of a ‘‘zip
code’’ speci¢c for tumor vessels could be circumvented by target-
ing an antimitotic reagent to all vessels, independent of their ana-
tomic distribution. This strategy should prevent endothelial
mitosis in all tissues, but, given the extremely low mitotic index
in normal tissues, it should primarily a¡ect tumor vessels and not
quiescent endothelial cells of normal tissues. In theory, all drugs
currently used to prevent mitosis of cancer cells should also pre-
vent mitosis of endothelium, but so far this ‘‘side-e¡ect’’ of anti-
cancer drugs has not e¡ectively been exploited to achieve antian-
giogenesis. One reason is that delivery schedules and drug doses
are not adjusted to cell cycle conditions of endothelial cells,
which is in part addressed by modifying chemotherapeutic treat-
ment to a continuous, low dose, ‘‘metronomic’’ regimen (Browder
et al, 2000; Klement et al, 2000; Gasparini, 2001). Another reason
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is that drug distribution and compartmentation do not favor ves-
sels, which is addressed by coupling therapeutic agents to integ-
rin-binding motifs (Arap et al, 1998; Ellerby et al, 1999).
We wished to exploit the antiangiogenic potential of paclitaxel
(Taxols). Paclitaxel is an alkaloid, which stabilizes microtubules
and demonstrates marked activity against several tumors, but also
inhibits endothelial cell proliferation, motility, and tube forma-
tion (Belotti et al, 1996; Lau et al, 1999). The use of paclitaxel is
limited by its low therapeutic index: it is highly lipophilic and
practically insoluble in water. The commercially available injec-
tion preparation is a sterile solution of the drug in Cremophor
ELs and dehydrated alcohol, which has serious side-e¡ects. To
circumvent this problem, paclitaxel has been encapsulated in li-
posomes, microparticulate lipoidal vesicles (Sharma et al, 1996;
Cabanes et al, 1998), but previous studies using liposomal drugs
have been hindered by the rapid clearance of the liposome by
cells of the reticuloendothelial system. New developments in
liposome technology now provide an opportunity to enhance
the therapeutic index and to alter the biodistribution of paclitax-
el. Cationic liposome preparations were shown to escape reticu-
loendothelial degradation and to be enriched within vessel walls
(Hashizume et al, 1997; Liu et al, 1997; McLean et al, 1997; Harigai
et al, 2001; Ramesh et al, 2001). Angiogenic endothelial cells ap-
peared to have an improved uptake of cationic liposomes com-
pared to the corresponding normal endothelial cells (Thurston
et al, 1998).
In this study, we wished to take advantage of a cationic lipo-
some preparation, where the lipid composition and charge have
been optimized for e⁄cient encapsulation of paclitaxel and for
delivery to blood vessels. We used a humanized SCID mouse
model allowing us to analyze orthotopic growth of human mel-
anoma cells on human dermis.We show that paclitaxel encapsu-
lated in liposomes (LP), but not paclitaxel in Cremophor ELs,
prevents tumor angiogenesis and melanoma growth.
MATERIALS AND METHODS
Cell lines A-375 human melanoma cells (American Type Culture
Collection, Manassas, VA) were grown in RPMI 1640 medium
supplemented with 5% fetal bovine serum (FBS), 50 U per ml penicillin,
50 mg per ml streptomycin, and 2 mM glutamine (all from Life
Technologies, Paisley, UK). Human umbilical vein endothelial cells
(HUVEC) were isolated and cultured in Iscove’s modi¢ed culture
medium (Life Technologies) supplemented with 20% FBS, endothelial
cell growth supplement (4 ml per ml, Promo Cell, Heidelberg, Germany),
L-glutamine, and antibiotics as described previously (Petzelbauer et al, 1993).
Liposome preparation Cationic liposomes with a total lipid content of
50 mM were prepared by the lipid ¢lm method followed by several cycles
of extrusion. Brie£y, 0.25 mmol 1,2-dioleoyl-3-trimethylammonium
propane and 0.235 mmol 1,2-dioleoyl-sn-glycero-3-phosphocholine (both
from Avanti Polar Lipids, Alabaster) with or without 0.015 mmol
paclitaxel were dissolved in 15 ml chloroform. The respective mixture was
gently warmed to 401C in a round-bottomed £ask and the solvent was
evaporated under vacuum in a rotary evaporator until a thin lipid ¢lm
was formed. Solvent traces were eliminated by drying the ¢lm at 5 mbar
for 60 min. Multilamellar liposomes formed spontaneously upon addition
of 10 ml 5% glucose (wt/vol) to the £ask. The suspension was left
overnight to allow swelling of the liposomes. Next, the suspension was
extruded ¢ve times in a 10 ml extruder (Lipex,Vancouver, Canada) with a
thermobarrel thermostatted at 301C. The pore size of the polycarbonate
membrane (Osmonics, Minnetonka, MN) was 200 nm. The resulting
suspension was stored at 41C under argon. The particle size of the
liposomes was analyzed by photon correlation spectroscopy using a
Malvern Zetasizer 3000 (Malvern Instruments, Herrenberg, Germany).
Typically, the suspensions exhibited a Zaverage of 180^200 nm. Lipid and
paclitaxel concentrations were determined by high performance liquid
chromatography using a UV/VIS detector (205 nm for lipids, 227 nm for
paclitaxel). The separation and quanti¢cation of the components was
carried out using a C8 LiChrospher 60 RP-select B column (250 4 mm,
5 mm particle size) with a C18 precolumn.
Animals Female CB17 SCID mice at an age of 6 wk were from
Bomholtgard (Bomice, Denmark). Details of animal housing have been
described previously (Petzelbauer et al, 1996). NMRI nude mice were
from D’Elevage Janvier. All experiments were approved by the University
of Vienna Animal Care and Use Committee.
Human skin and melanoma engraftment Normal human skin was
obtained from cadaveric donors within 6 h following death (Department
of Pathology, University of Vienna Medical School). All experimental
protocols were approved by the University of Vienna Ethical Committee.
After removal of the epidermis and the super¢cial portion of the dermis
using a dermatome, 0.8 mm thick sheets of the deep reticular dermis were
harvested with a dermatome and then cut into pieces of 2010 mm and
kept in phosphate-bu¡ered saline (PBS) at 41C. Engraftment was
performed within the next 4 h. Skin from a total of nine di¡erent donors
was used for the experiments shown. Mice were anesthetized as described
previously (Petzelbauer et al, 1996), the backs were incised, and a pocket was
prepared by separating the mouse epidermis and dermis from the
underlying fascia. Human grafts were placed into these pockets and ¢xed
with surgical staples (3M, St. Paul, MN) as described previously (Kunstfeld
et al, 1997). Two weeks after skin engraftment, 2107 A-375 melanoma
cells suspended in 200 ml PBS were injected into the back of each mouse,
below the mouse epidermis and above the human graft.The position of the
tip of the injection needle was easily controlled, because of the higher
resistance of the human dermis compared with the mouse dermis. In
selected experiments, the exact injection site was controlled by trypan
blue injection. Fourteen days later, clearly palpable nodules were seen in
495% of the mice (mice without tumors were excluded from further
evaluations) and treatment was initiated as described below.
Experimental protocol Mice were randomized into four treatment
groups: (i) treatment with LP [the paclitaxel concentration was 1.03 mg
per ml, and each mouse received 12.5 mg paclitaxel per kg body weight
coupled to liposomes (the lipid dose was E420 mg per kg body weight);
body weights were in the range of 20 g, i.e., injection volumes were in the
range of 250 ml]; (ii) treatment with liposomes (E420 mg total lipid per kg
body weight injection); (iii) treatment with paclitaxel (Taxols); each
mouse received 12.5 mg paclitaxel per kg body weight per injection; (iv)
treatment with 5% glucose [equal injection volume as in (c)].
Injections into the tail vein were performed three times a week (injection
time approximately 1^2 min). Tumor sizes were determined every second
day blinded to the treatment conditions by measuring the length and
width of the nodules with a caliper. Tumor volumes were calculated
by using the equation V¼ (p/6) (length) (width)2. After 2 wk of
treatment, mice were sacri¢ced by cervical dislocation. The tumors, lung,
liver, and spleen were harvested, and halves of the tissues were snap frozen
and stored at ^801C and the other halves were ¢xed in formaldehyde and
embedded in para⁄n. For the survival experiments, mice were monitored
daily. Endpoint was spontaneous death or signs of paralysis, serious
dyspnea, or serious cachexia.
Ultrasound examination On days 1 and 12 after initiation of therapy,
tumor invasiveness was evaluated with a 6^12 MHz linear array
ultrasound probe with three-dimensional features (Combison 530Dr,
Kretztechnik Austria, probe S-VNW 6^12). Mice were manually ¢xed
and ultrasound gel was placed at the interface between the tumor and the
ultrasound probe. Measurements were taken in the multiplanar mode
showing three perpendicular planes of the scanned volume. Volume data
sets were composed and stored on 540 megabyte 3.5 in. optical disks for
later evaluation.
Histology and immunohistochemistry Para⁄n-embedded tissues
were cut in 5 mm sections and stained with hematoxylin and eosin
according to standard procedures. Where indicated, sections were
depara⁄nized and a three-step immunohistochemistry was performed as
described previously (Gr˛ger et al, 1999), using a polyclonal rabbit anti-
von Willebrand factor (vWF, Dako, Glostrup, Denmark) diluted 1:100 in
PBS as a ¢rst step reagent, followed by a biotin-conjugated goat antirabbit
antibody (Vector Laboratories, Burlingame, CA, 1:100). Bound antibodies
were visualized using a horseradish-peroxidase-conjugated ABC kit
according to the instructions from the manufacturer (Vector Laboratories).
The polyclonal anti-vWF antibody recognizes human as well as mouse
vessels. The numbers of vWF-positive vessels were counted in all tumor
specimens (n¼ 45) in eight randomly selected high power ¢elds each by
two independent observers.
For immuno£uorescence studies, small aliquots from all tumor
specimens (n¼ 45) were snap frozen and cut into 5 mm cryostat sec-
tions and incubated with a mixture of mouse antihuman CD31
(Immunotech, France, 1 mg per ml) and a hamster antimouse CD31
(Endogen, Boston, MA, 1 mg per ml). Following rinsing, sections were
incubated with a TRITC-conjugated goat antimouse F(ab)2 antibody
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(Jackson, West Grove, PA, 1:150) and a biotinylated antihamster antibody
followed by incubation with FITC-conjugated avidin (Molecular Probes,
OR, 1 : 200).
In selected experiments, rhodamine-labeled cationic liposomes were
injected intravenously into the tail vein of LP-, paclitaxel-, or liposome-
treated animals at day 12. Twelve hours later, mice were sacri¢ced; the
tumors were harvested, snap frozen, cut into 5 mm cryostat sections and
stained with the rabbit anti-vWF antibody followed by incubation with
an FITC-conjugated antirabbit monoclonal antibody (Jackson; 1 : 100).
vWF-positive vessels (green) and deposits of rhodamine-labeled cationic
liposomes (red) were analyzed with a laser scan microscope (Zeiss,
Germany).
To determine numbers of cycling endothelial cells, 5-bromo-2-
deoxyuridine (BrdU; 0.8 mg per mouse) was injected intraperitoneally at
day 12 into LP-, paclitaxel-, or liposome-treated animals. Twelve hours
later, injections were repeated. Another 12 h later, animals were sacri¢ced
and the tumors, livers, and lung were harvested and embedded in OCT
compound medium (Sakura, Torrence, CA). Cryostat sections were
subjected to triple staining. Brie£y, sections were pretreated according to
the instructions of the BrdU-labeling kit from Zymed (San Francisco,
CA) and BrdU incorporated into nuclei was detected with a mouse anti-
BrdU monoclonal antibody (Neomarkers, Fremont, CA, 1:1000) followed
by incubation with an FITC-conjugated antimouse monoclonal antibody
(Sigma, Steinheim, Germany 1:80). Vessels were labeled with rabbit anti-
vWF monoclonal antibody (Dako; 1:100) followed by Cy5-conjugated
goat antirabbit F(ab)2 (Jackson; 1:100). Nuclei were stained red by
incubation with propidium iodide (Sigma, 1:1500). Sections were
examined with a laser scan microscope. BrdU-labeled endothelial nuclei
appeared yellow (overlay of red and green) within vWF-positive vessels
(blue) and were counted by two independent observers and expressed as a
percentage of total endothelial nuclei (red plus yellow appearing nuclei
within vessel walls stained in blue).
Proliferation assays in cell culture HUVEC or A-375 were seeded in
gelatin-coated C6 well plates (5104 cells per well) and cultured in the
presence of paclitaxel (dose range 102^104 ng per ml), LP (containing
paclitaxel in a dose range of 102^104 ng per ml encapsulated
in liposomes), or liposomes without paclitaxel. Culture medium
supplemented with the respective additives was renewed at day 2. To test
whether paclitaxel caused irreversible inhibition of endothelial
proliferation, culture medium was renewed on day 4 and indicated
additives were withdrawn from the medium. Cell numbers were
evaluated on days 1, 2, 3, 4, 7, and 11 using a Coulter counter.
Measurement of rhodamine-labeled liposome concentrations
within blood and tissues Rhodamine-labeled cationic liposomes
(10 mM total lipid) were prepared by the lipid ¢lm method followed by
several cycles of extrusion (for details see Liposome preparation). For
pharmacokinetic studies liposomes were injected intravenously into NMRI
nude mice (40 mg total lipid per kg body weight) and blood samples were
collected 1 min, 5 min, 10 min, 20 min, 45 min, and 60 min thereafter. For
determination of the £uorophore content of tumor tissue, tumor samples
were homogenized. Liposomal concentrations were then indirectly
determined by measuring the rhodamine content by £uorescence
spectroscopy (Fluoromax 2, Jobin Yvon, Grasbrunn, Germany) at
rhodamine-speci¢c parameters (excitation 560 nm, emission 580 nm).
Measured £uorescence values were corrected for background levels.
RESULTS
Tumor growth and invasiveness is retarded by LP
in vivo Mice without clearly visible tumors 14 d after tumor
inoculation were excluded from further studies. The remaining
animals were randomized into four treatment groups as
described in Materials and Methods (mean tumor volume 276725
mm3). In mice treated with paclitaxel, glucose, or liposomes,
tumors continuously enlarged and after 12 d of treatment tumor
volumes were in mean 15-fold the size seen at the starting point
(Fig 1A). In contrast, in mice treated with LP, tumor volumes
increased only by a factor of 4 and were signi¢cantly smaller
than tumors in the other three treatment groups (Fig 1A,
p40.05). Tumor invasiveness was evaluated by sonography at the
onset of treatment (day 1, n¼ 6 in each group) and prior to
sacri¢ce (day 12, n¼ 6 in each group). All tumors (6 of 6) in
mice treated with LP showed well-de¢ned borders towards the
underlying human skin graft at 12 d of treatment (an example is
shown in Fig 1B ^ the human dermal graft is displayed as a
continuous and ultrasonically dense area). In contrast, in mice
treated with paclitaxel, tumors were penetrating the human
grafts and formed deep protrusions into the underlying tissues
(Fig 1C).
We next tested survival of mice. Each treatment group initially
consisted of 12 mice, but tail vein thrombosis in some mice
precluded further drug application and these mice had to
be excluded from further evaluation. In LP-treated animals,
six of nine mice survived at day 43 after onset of treatment,
in paclitaxel-treated animals three of 11 mice, and in
Figure1. Tumor growth, invasiveness, and survival. (A) Summary of
tumor growth curves in SCID mice engrafted human dermis and with
2107 A-375 melanoma cells. Treatment was performed with 12.5 mg per
kg LP, 12.5 mg per kg paclitaxel solubilized in Cremophor ELs, lipo-
somes, or glucose. (B), (C) Sonography of tumors revealed sharply demar-
cated nodules in animals treated with LP; the human graft is seen as a dense
band below the tumor (B, arrow). In contrast, in animals treated with pacli-
taxel (pac), the human dermal graft was disrupted by tumor protrusions
reaching deeply down into the underlying tissue (C, arrows). (D) Survival
rates in SCID mice engrafted with A-375 melanoma cells. Treatment was
performed with 12.5 mg per kg LP, 12.5 mg per kg paclitaxel solubilized in
Cremophor ELs or glucose. (E) Dose^response kinetic in nude mice en-
grafted with A-375 melanoma cells; Treatment was performed with LP
containing indicated concentrations of paclitaxel.
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glucose-treated animals none of 11 mice survived day 37
(Fig 1D).
Dose titration with LP was performed in nude mice instead of
SCID mice and without the human dermal graft. A-375
melanoma cells were injected subcutaneously. The maximum
dose of paclitaxel encapsulated in liposomes was 12.5 mg per kg
and this was the most e¡ective concentration; 5 mg per kg was
less e¡ective and 2.5 mg per kg had only minor e¡ect compared
with the glucose control (Fig 1E).
Vascularization of tumor margins at the interface to the
human dermis is diminished by LP in vivo Hematoxylin
and eosin staining of the interface between tumor and the
human dermal graft revealed sharply demarcated tumors in
animals treated with LP after 12 d of treatment. The tumors
were encapsulated by thin bundles of ¢brous tissue; vessels were
sparse at the border of the tumor (Fig 2A). In contrast, in mice
treated with paclitaxel, the interface between tumor and dermal
graft was ill de¢ned, and small groups of tumor cells were seen
within the human dermis and were surrounded by dilated vessels
(Fig 2B). Quanti¢cation of vessel cross-sections (by anti-vWF
staining on para⁄n sections, which identi¢es human as well as
mouse vessels, Fig 2C,D) con¢rmed the histologic impression:
numbers of vessels per high power ¢eld were signi¢cantly less in
LP-treated mice compared with paclitaxel- and liposome-treated
mice, respectively, po0.05 (Fig 3). Hematoxylin and eosin
staining revealed the central portions of the tumors to be
necrotic or apoptotic. The proportions of viable and dead tumor
cells were approximately equal in all treatment groups (data not
shown).
It should be noted that the human graft is vascularized by
human as well as by mouse vessels; their ratio (human:mouse
vessels) was approximately 1:1 and was comparable in LP-treated
animals and controls (representative example shown in Fig
2E,F), suggesting that LP impaired proliferation of human as
well as mouse vessels. Podoplanin-positive vessels (lymphatic
vessels) were absent within the tumors and within the human
grafts (data not shown, determined by an antipodoplanin
polyclonal rabbit antibody, gift from Dr. Dontscho Kerjaschki,
Department of Pathology, University of Vienna).
Based on a previous study showing that cationic liposomes
bind to and are internalized by endothelial cells (Thurston et al,
1998), we analyzed the distribution of liposomes by using
rhodamine-labeled liposomes. Mice treated with LP or with
paclitaxel for 12 d were injected with rhodamine-labeled
liposomes and sacri¢ced 12 h later. Tissues were analyzed by laser
scan microscopy. In both treatment groups £uorescent signals
were detectable within vessel walls, indicative for vascular
targeting (Fig 2G,H). It should be noted that in mice treated
with LP, in addition to the staining of the vessel wall, there was
some perivascular accumulation of £uorescence, indicating a
vascular permeability in this treatment group (Fig 2G). This
¢nding was con¢rmed by homogenizing tumor tissue and
quantifying the total £uorophore content, revealing an
approximately 5-fold higher £uorophore content in LP-treated
compared with paclitaxel- or liposome-treated tumor tissues
(n¼ 4 in each group; 2.871.4 mg compared with 0.670.2 and
0.570.2 mg rhodamine per g tissue; po0.001). It should be
noted that rhodamine-conjugated liposomes were also seen
within vessels of mouse lungs and livers and in Kup¡er cells
(data not shown).
The mitotic index of endothelium is reduced by LP
in vivo BrdU, a thymidine analog incorporated into the DNA of
cells during the S-phase, was injected into LP- or paclitaxel-treated
Figure 2. Histology and immunohistology. (A), (B) Formalin-¢xed,
para⁄n-embedded tissues were stained with hematoxylin and eosin. The
interface between the tumor and the human dermis is sharply demarcated
in LP-treated animals (A), whereas in paclitaxel (pac)-treated animals the
tumor is invading the dermal graft. These tumor protrusions are sur-
rounded by newly formed vessels (B). (C), (D) Formalin-¢xed, para⁄n-
embedded tissues were depara⁄nized and stained with anti-vWF (red)
and counterstained with hematoxylin (blue). Areas of melanoma cell ne-
crosis (small, pycnotic cells) are seen in LP-treated (C) and in paclitaxel-
treated (D) animals; gross microscopic examination does not reveal ob-
vious di¡erences in vessel densities within the tumors between the treat-
ment groups. (E), (F) Frozen tissue sections were double-stained with
human (red) and mouse (green) CD31 monoclonal antibodies to identify
vessel origins at the interface between the human dermal graft and the mel-
anoma. In both LP-treated (E) and paclitaxel-treated (F) animals, mouse
vessels were found within the human graft in approximately equal num-
bers. (G), (H) Following 14 d of LP (G) or paclitaxel (H) treatment, ani-
mals were injected with rhodamine-conjugated liposomes as described in
Materials and Methods; tissues were harvested, snap frozen, stained with
anti-vWF antibodies, and analyzed by laser scan microscopy.Vessels stained
with anti-vWF appear green, rhodamine-labeled liposomes appear red, co-
localization is yellow.
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animals and BrdU incorporation was determined by immuno-
histochemistry 24 h later. This time interval between BrdU
injection and tissue analysis has proven optimal to analyze cells
with a low mitotic index, such as endothelium. It should be noted
that, according to this protocol, numbers of BrdU-positive cells
correlate to the numbers of cells undergoing mitosis during the last
24 h and are thus higher than one would expect in a ‘‘one shot
image’’. Figure 4 gives representative examples of human dermal
grafts adjacent to tumors and livers in LP- compared with
paclitaxel-treated animals (triple-staining: propidium iodide in red
for all nuclei, anti-BrdU in green for cells that underwent S-phase
during the last 24 h, and anti-vWF vessels in blue). Whereas
21.9%73.65% of endothelial cells at the margins of the tumor
were found reactive with the anti-BrdU antibody in paclitaxel-
treated animals, only 6.4%71.7% of endothelial cells had
incorporated BrdU in mice treated with LP. In livers, analyzed for
comparison, 6% of endothelial cells were found to be BrdU
positive, irrespective of whether animals were treated with LP or
with paclitaxel. BrdU incorporation into tumor cells was not
valuable, because 490% of nuclei of melanoma cells had
incorporated BrdU, irrespective of the treatment. This was also true
for nuclei of the outer hair root sheaths (data not shown),
con¢rming that a BrdU uptake for 24 h is not suitable for
analyzing the mitotic index of highly proliferative cells.
Antiproliferative e¡ect of paclitaxel on HUVEC and on A-375
cells in vitro Proliferation of HUVEC in culture was abrogated
at a paclitaxel concentration of 0.001 ng per ml (Fig 5A). It should
be noted that in cell culture LP and paclitaxel had identical
antiproliferative e¡ects (Fig 5B). After paclitaxel withdrawal,
endothelial cells remained growth arrested for 3 d; thereafter
endothelial cell growth rates were restored (data not shown).
Proliferation of A-375 melanoma cells was abrogated at 10-fold
higher concentrations of paclitaxel (0.01 ng per ml; Fig 5A).
It should be noted that we could not directly compare
concentrations of paclitaxel in cell culture with those in the blood
of our SCID mice, because for technical reasons paclitaxel
concentrations in the blood could not be measured. Instead, we
determined concentrations of rhodamine-labeled liposomes,
which we expected to have pharmacokinetics similar to LP. Ten
minutes after intravenous injection, 75% of rhodamine was
cleared from the blood (plasma concentrations were zero; 25% of
the rhodamine was found within the corpuscular fraction of the
blood). After 60 min 95%, and after 120 min 100%, of
rhodamine was cleared from the blood. Given the injection
protocol in our animal experiments (every third day), it can be
assumed that therapeutic serum concentrations were reached only
during the ¢rst 10 min after injection.
DISCUSSION
We have established a small humanized animal model to analyze
melanoma growth, which has several advantages. First, treatment
is initiated on an already established tumor. Second, the tumor is
grown orthotopically in that human melanoma cells grow on
and invade human dermis. Third, the tumor is at least partially
nourished from human vessels. Fourth, not only tumor growth
but also animal survival serves as an endpoint. Using this model,
we show that LP diminishes tumor growth and invasiveness and
improves survival compared with controls treated with soluble
paclitaxel, liposomes, or glucose.
The strong antitumor e¡ects of LP compared with the small
e¡ects seen with paclitaxel solubilized in Cremophor ELs were
surprising. Equal amounts of paclitaxel were delivered with both
application procedures. Both formulations were equally antiproli-
ferative on endothelial cells in culture. Extended circulation half-
life of LP is also unlikely to be the reason: in analogy with the
pharmacokinetics of rhodamine-labeled liposomes, it is reason-
able to assume that also blood concentrations of LP were zero
Figure 3. Quanti¢cation of vessel cross-sections. Formalin-¢xed tis-
sues were stained with anti-vWF antibodies (as shown in Fig 2C, D) and
numbers of vessel cross-sections were counted by two independent obser-
vers (RK and GW) blinded to the treatment conditions (paclitaxel encap-
sulated in liposomes, LP; paclitaxel, pac; liposome, lip). Results are shown
as mean7SD.
Figure 4. Mitotic endothelial cells within the mouse liver and with-
in the human skin graft adjacent to the tumor. Animals were injected
with BrdU as described inMaterials and Methods. BrdU-positive nuclei were
identi¢ed by immuno£uorescence triple-staining using anti-BrdU antibo-
dies (green), propidium iodide to stain nuclei (red), and anti-vWF antibo-
dies to stain vessels (blue). Mitotic endothelial cells appear yellow (overlaid
red and green) and are located within blue areas (vessel walls). The top four
panels give representative examples of such stainings. The black and white
images below show the BrdU-positive cells (green channel only). Quanti-
¢cation is shown below (% of BrdU-positive endothelial cells out of all
endothelial cells); in each sample eight high power ¢elds were counted by
two independent observers blinded to the treatment condition.
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after 2 h. Given the treatment intervals of 3 times per wk, con-
tinuous antiproliferative blood concentrations of paclitaxel can be
excluded. The bio-distribution of our rhodamine-labeled lipo-
somes is in striking congruency with the biologic e¡ects of LP,
namely the decreased mitotic index of endothelial cells, which
favors the conclusion that vessels are the preferential target of
our cationic liposome preparation. A preferential targeting of an-
giogenic vessels with cationic liposomes has already been shown
previously byThurston et al (1998). Interestingly, the constitutive
mitotic index of normal endothelium remained unaltered, yet
the cause for this observation has to remain unanswered. It might
be speculated that factors governing constitutive mitosis are dif-
ferent from those inducing mitosis in angiogenic vessels, the for-
mer being paclitaxel insensitive, the latter sensitive to this drug.
An interesting observation was that tumors in LP-treated ani-
mals were not only growth retarded but also had sharply demar-
cated ¢brous capsules. One reason may be a direct e¡ect of
paclitaxel on tumor cell motility. We favor the assumption that
the reduced vessel formation at the interface between tumor and
the stroma prevented the formation of protrusions by starving
the tumor, the ¢brous tissue reaction being a hypoxic response
of ¢broblasts (Norman et al, 2000;Tajima et al, 2001).
Another ¢nding deserves comment, namely the increased per-
meability of vessels for liposomes in LP-treated animals. There is
evidence that paclitaxel impairs cell^cell adhesion by activating
caspases and subsequent proteolysis of catenins (Ling et al, 2001),
but in this study paclitaxel concentrations were 100-fold higher
than those required to inhibit proliferation of endothelial cells in
culture. Thus, in order to exert such an e¡ect, paclitaxel has to
accumulate in endothelial cells, a situation that might be present
in animals treated with LP. Indirect evidence for the assumption
that targeting cytotoxic reagents to blood vessels by the use of
liposomes results in a decreased endothelial barrier function
comes from a study using liposome-encapsulated doxurubicin,
where the authors found large areas with hemorrhage around
tumor vessels associated with increased tumor cell necrosis (Zhou
et al, 2002).
Others have previously encapsulated cytotoxic agents into
liposomes and tested them in animal models. The approach of
Sharma et al (1996) was to encapsulate paclitaxel into neutral lipo-
somes. These authors injected paclitaxel encapsulated in neutral
liposomes every 2 d into tail veins of mice and found an im-
proved antitumor e⁄cacy compared with paclitaxel in Cremo-
phor ELs. They assumed that a sustained paclitaxel release from
liposomes was the basis of the improved antitumor e¡ect com-
pared with paclitaxel in Cremophor ELs. As they did not use
cationic liposomes and did not analyze the distribution of lipo-
somes within tissues, the mechanism of action in their experi-
ments remains open, but it can be assumed that the liposomes
passively accumulated in tumor tissue due to an enhanced
permeation through vascular pores (Oku et al, 2000). Others have
targeted liposome-coupled cytostatic drugs to tumor cells by, for
example, injecting doxorubicin-coupled liposomes conjugated to
an anti-b1 integrin antibody, which improved survival of animals
(Sugano et al, 2000). Interestingly, their liposomal-coupled doxor-
ubicin without the targeting antibody showed no e¡ect, which
might have been for the following reasons: either their liposomal
preparation did not target vessels or their injection intervals of 7
d were too long to maintain an antiangiogenic doxorubicin level
within endothelial cells. Our in vitro data postulate that, following
withdrawal of paclitaxel, endothelial growth arrest persists for 3
d, which would suggest incomplete inhibition of angiogenesis
with injection intervals longer than 3 d.This might be the reason
for the poor outcome of clinical cancer trials using paclitaxel
every 7^21 d (Nabholtz et al, 1996; Chang et al, 1997; Forastiere
et al, 2001) and the promising results of a phase I study employing
daily infusions of paclitaxel (Rathmann et al, 1999). It should be
noted that the amount of paclitaxel per kilogram body weight
injected into our mice was clearly higher than that in human stu-
dies.We have maximized the paclitaxel content of our liposomes,
whereby the total concentration of paclitaxel per kilogram was
limited by the maximal possible injection volume.Within the ob-
servation period of up to 6 wk, no clinically visible side-e¡ects
occurred, and peripheral blood counts were comparable to those
of control animals (data not shown).
In conclusion, this study exploits the situation that endothelial
cells of tumor vessels have high mitotic indices whereas endo-
thelial cells of normal tissues hardly divide.We show that target-
ing an antimitotic drug to vessels prevents angiogenesis and
as a consequence tumor growth. We have chosen paclitaxel
because of its known antiangiogenic activity at low concentra-
tions and its availability. From the encouraging results of
this study it can be expected that other drugs will serve a similar
function when coupled to appropriate carriers and that such
carriers need not necessarily distinguish between normal and
tumor vessels. Side-e¡ects of such a system can be expected to
be low due to the low mitotic index of normal endothelium.
It should be noted that the treatment protocol used here,
like other antiangiogenic reagents (Featherstone and Gri⁄ths,
2002), does not shrink tumors; thus in cancer patients it has to
be combined with traditional chemotherapy, radiation, and/or
immunotherapy.
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